Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer

Publisher： Karger

E-ISSN： 1423-0232|73|3-4|221-227

ISSN： 0030-2414

Source： Oncology, Vol.73, Iss.3-4, 2008-04, pp. : 221-227

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 159-163

Karger

Access to resources Recommend Favorite

What Else in Gemcitabine-Pretreated Advanced Pancreatic Cancer? An Update of Second Line Therapies

By  

Reviews on Recent Clinical Trials, Vol. 5, Iss. 1, 2010-01 ,pp. : 43-56

Bentham Science Publishers

Access to resources Recommend Favorite

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 270-274

Karger

Access to resources Recommend Favorite

Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer

By  

Oncology, Vol. 67, Iss. 2, 2004-10 ,pp. : 93-97

Karger

Access to resources Recommend Favorite

An Open-Label, Multicenter Study of Outpatient Capecitabine Monotherapy in 631 Patients with Pretreated Advanced Breast Cancer

By  

Oncology, Vol. 72, Iss. 1-2, 2007-11 ,pp. : 51-57

Karger

Access to resources Recommend Favorite